IP Library Granted Patent US 8,124,109
Granted Patent B2
US 8,124,109 · App. 12/467,255 · Granted Feb 28, 2012

Vault compositions for immunization against chlamydia genital infection

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,109
App. No.
12/467,255
Granted
Feb 28, 2012
Kind
B2
Abstract

Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal mucosa. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity at mucosal surfaces while reducing inflammation associated with Chlamydia infection.

Claims (5)

1. A pharmaceutical composition for immunizing a subject against C. trachomatis genital infection, comprising a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle, and at least one pharmaceutically acceptable excipient, wherein the vault-like particle comprises MVP.

2. The pharmaceutical composition of claim 1 , wherein the vault-like particle further comprises VPARP or modified VPARP, or a portion of VPARP or a modified portion of VPARP.

3. The pharmaceutical composition of claim 1 , wherein the MVP is modified by the addition of an amino acid sequence added to the N-terminal of the MVP.

4. The pharmaceutical composition of claim 3 , wherein the immunogenic peptide or immunogenic fragment or variant thereof resides within the vault-like particle.

5. The pharmaceutical composition of claim 1 , wherein the immunogenic peptide is MOMP.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 27, 2010
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024748/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2010
From: ROME, LEONARD H.; KELLY, KATHY A.; KICKHOEFER, VALERIE A.; CHAMPION, CHERYL I.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023907/0670 →
CONFIRMATORY LICENSE Recorded Jun 8, 2009
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022790/0731 →
Continuity (2)
Provisional Application 61053623 · May 15, 2008
Related Publication 20090304751A1 · Dec 10, 2009